Jefferies Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jefferies Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$83.7M	Buy	1,055,600 +472,600	+81%	+$39.8M	0.7%	23
2022 Q2	$43.3M	Sell	583,000 -403,900	-41%	-$30.3M	0.36%	46
2022 Q1	$88.7M	Buy	986,900 +663,100	+205%	+$61.2M	0.56%	25
2021 Q4	$36.3M	Buy	323,800 +11,400	+4%	+$1.37M	0.21%	72
2021 Q3	$39.3M	Buy	+312,400	New	+$40.2M	0.29%	55
2021 Q2	–	Sell	-147,000	Closed	-$19.9M	–	2048
2021 Q1	$19.9M	Sell	147,000 -28,000	-16%	-$4.19M	0.17%	94
2020 Q4	$24.6M	Buy	175,000 +165,000	+1,650%	+$21.1M	0.19%	76
2020 Q3	$1.11M	Sell	10,000 -25,900	-72%	-$2.9M	0.01%	763
2020 Q2	$4.02K	Sell	35,900 -233,100	-87%	-$23M	0.05%	328
2020 Q1	$20.8M	Buy	269,000 +219,000	+438%	+$19.4M	0.23%	63
2019 Q4	$4.76M	Sell	50,000 -130,000	-72%	-$11.2M	0.04%	540
2019 Q3	$13.7M	Sell	180,000 -7,500	-4%	-$623K	0.11%	139
2019 Q2	$16.4M	Sell	187,500 -491,600	-72%	-$41.9M	0.12%	126
2019 Q1	$61.5M	Buy	679,100 +148,800	+28%	+$12.7M	0.51%	20
2018 Q4	$38M	Buy	530,300 +108,600	+26%	+$8.75M	0.31%	46
2018 Q3	$40.4M	Sell	421,700 -821,600	-66%	-$79.7M	0.26%	47
2018 Q2	$118M	Buy	1,243,300 +1,050,200	+544%	+$96.5M	0.66%	19
2018 Q1	$16.9M	Buy	193,100 +2,600	+1%	+$237K	0.09%	142
2017 Q4	$16.2M	Sell	190,500 -298,100	-61%	-$25M	0.08%	178
2017 Q3	$42.3M	Sell	488,600 -914,300	-65%	-$73.3M	0.28%	45
2017 Q2	$108M	Buy	1,402,900 +1,186,400	+548%	+$84.1M	0.72%	12
2017 Q1	$15M	Sell	216,500 -889,400	-80%	-$59.7M	0.11%	160
2016 Q4	$65.5M	Buy	1,105,900 +975,900	+751%	+$60.2M	0.37%	35
2016 Q3	$8.62M	Buy	+130,000	New	+$8.04M	0.04%	360
2015 Q4	–	Sell	-200,000	Closed	-$12.4M	–	2613
2015 Q3	$12.4M	Buy	+200,000	New	+$15.8M	0.07%	212
2015 Q1	–	Sell	-56,100	Closed	-$3.49M	–	2432
2014 Q4	$3.49M	Buy	+56,100	New	+$3.2M	0.02%	521

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jefferies Group's XBI Position: Q3 2022 in Review

Jefferies Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 93% in Q3 2022, selling an estimated $35.8M and leaving 31,002 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #535.

Jefferies Group first reported a position in XBI in Q3 2014 and has held it in 31 quarters since. The position peaked at $65.5M in Q1 2022. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Jefferies Group held 31,002 shares of State Street SPDR S&P Biotech ETF worth $2.46M as of Q3 2022.
Jefferies Group sold 424,343 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $35.8M.
State Street SPDR S&P Biotech ETF made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #535 holding.
Jefferies Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2014 and has held it in 31 quarters since.
Jefferies Group's State Street SPDR S&P Biotech ETF position peaked at $65.5M in Q1 2022.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.